Hemorrhagic stroke and oral anticoagulants: What is to be done?
Hemorrhagic stroke (HS) is associated with high mortality and disability rates. Due to the introduction of the current guidelines for the prevention of systemic thromboembolic events in patients with atrial fibrillations and to an increase in the number of older patients, there has been a rise in th...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2016-03-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/585 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850186777578438656 |
|---|---|
| author | M. A. Domashenko |
| author_facet | M. A. Domashenko |
| author_sort | M. A. Domashenko |
| collection | DOAJ |
| description | Hemorrhagic stroke (HS) is associated with high mortality and disability rates. Due to the introduction of the current guidelines for the prevention of systemic thromboembolic events in patients with atrial fibrillations and to an increase in the number of older patients, there has been a rise in the incidence of intracranial hemorrhage (ICH) associated with the use of oral anticoagulants. The paper discusses medical treatment in patients with HS during therapy with vitamin K antagonists (warfarin) and novel oral anticoagulants (dabigatran. rivaroxaban, apixaban), as well as an anticoagulant resumption policy after prior ICH in patients at high risk for thromboembolic events. |
| format | Article |
| id | doaj-art-95b8a250cc8b41e890d7f26ba8c83799 |
| institution | OA Journals |
| issn | 2074-2711 2310-1342 |
| language | Russian |
| publishDate | 2016-03-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Неврология, нейропсихиатрия, психосоматика |
| spelling | doaj-art-95b8a250cc8b41e890d7f26ba8c837992025-08-20T02:16:15ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422016-03-0181617010.14412/2074-2711-2016-1-61-70540Hemorrhagic stroke and oral anticoagulants: What is to be done?M. A. Domashenko0Neurology Research Center, Moscow, Russia 80, Volokolamskoe Shosse, Moscow 125367Hemorrhagic stroke (HS) is associated with high mortality and disability rates. Due to the introduction of the current guidelines for the prevention of systemic thromboembolic events in patients with atrial fibrillations and to an increase in the number of older patients, there has been a rise in the incidence of intracranial hemorrhage (ICH) associated with the use of oral anticoagulants. The paper discusses medical treatment in patients with HS during therapy with vitamin K antagonists (warfarin) and novel oral anticoagulants (dabigatran. rivaroxaban, apixaban), as well as an anticoagulant resumption policy after prior ICH in patients at high risk for thromboembolic events.https://nnp.ima-press.net/nnp/article/view/585hemorrhagic strokeoral anticoagulants |
| spellingShingle | M. A. Domashenko Hemorrhagic stroke and oral anticoagulants: What is to be done? Неврология, нейропсихиатрия, психосоматика hemorrhagic stroke oral anticoagulants |
| title | Hemorrhagic stroke and oral anticoagulants: What is to be done? |
| title_full | Hemorrhagic stroke and oral anticoagulants: What is to be done? |
| title_fullStr | Hemorrhagic stroke and oral anticoagulants: What is to be done? |
| title_full_unstemmed | Hemorrhagic stroke and oral anticoagulants: What is to be done? |
| title_short | Hemorrhagic stroke and oral anticoagulants: What is to be done? |
| title_sort | hemorrhagic stroke and oral anticoagulants what is to be done |
| topic | hemorrhagic stroke oral anticoagulants |
| url | https://nnp.ima-press.net/nnp/article/view/585 |
| work_keys_str_mv | AT madomashenko hemorrhagicstrokeandoralanticoagulantswhatistobedone |